Arrow Greentech Ltd
Incorporated in 1982, Arrow Greentech
Ltd is in the business of bio-degradable (green) products, high-tech products and having Patents income for such products /technology[1]
- Market Cap ₹ 1,013 Cr.
- Current Price ₹ 670
- High / Low ₹ 953 / 342
- Stock P/E 15.1
- Book Value ₹ 173
- Dividend Yield 0.75 %
- ROCE 27.6 %
- ROE 19.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 74.4% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.0%
- Company's median sales growth is 18.6% of last 10 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 23 | 31 | 39 | 43 | 31 | 27 | 24 | 106 | 132 | 201 | 157 | 222 | |
| Sales growth | +14% | +14% | +36% | +25% | +12% | -28% | -15% | -11% | +341% | +25% | +52% | -22% | +41% |
| 11 | 11 | 15 | 27 | 46 | 28 | 23 | 29 | 78 | 80 | 118 | 101 | 134 | |
| Operating Profit | 9 | 12 | 16 | 12 | -3 | 4 | 3 | -5 | 28 | 52 | 83 | 56 | 87 |
| OPM % | 46% | 51% | 52% | 31% | -7% | 12% | 13% | -22% | 26% | 39% | 41% | 36% | 39% |
| 1 | 5 | 2 | 10 | 7 | 2 | 3 | 7 | 4 | 6 | 5 | 8 | 9 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 9 | 16 | 17 | 18 | 1 | 2 | 2 | -3 | 27 | 52 | 83 | 58 | 91 |
| Tax % | 30% | 29% | 18% | 16% | 81% | 7% | -57% | -43% | 29% | 25% | 25% | 27% | |
| 7 | 11 | 14 | 15 | 0 | 2 | 3 | -2 | 19 | 39 | 62 | 42 | 67 | |
| EPS in Rs | 5.20 | 8.91 | 10.95 | 12.02 | 0.15 | 1.50 | 1.79 | -1.21 | 12.51 | 26.05 | 41.03 | 28.16 | 44.46 |
| Dividend Payout % | 45% | 47% | 48% | 16% | 309% | 0% | 0% | 0% | 8% | 8% | 10% | 18% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 42% |
| 3 Years: | 14% |
| TTM: | 41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 74% |
| 3 Years: | 28% |
| TTM: | 53% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 39% |
| 3 Years: | 13% |
| 1 Year: | 18% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 26% |
| 3 Years: | 30% |
| Last Year: | 20% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 10 | 16 | 30 | 38 | 36 | 44 | 46 | 44 | 73 | 111 | 170 | 206 | 246 |
| 0 | 0 | 0 | 0 | 0 | 5 | 4 | 4 | 3 | 0 | 0 | 2 | 2 | |
| 9 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 15 | 10 | 12 | 11 | 18 | |
| Total Liabilities | 31 | 33 | 47 | 56 | 55 | 70 | 71 | 69 | 106 | 136 | 196 | 234 | 281 |
| 5 | 5 | 16 | 16 | 13 | 17 | 15 | 14 | 12 | 15 | 17 | 17 | 16 | |
| CWIP | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 1 |
| Investments | 15 | 16 | 19 | 26 | 12 | 11 | 6 | 2 | 1 | 37 | 82 | 113 | 166 |
| 9 | 11 | 11 | 14 | 28 | 42 | 50 | 52 | 92 | 81 | 95 | 103 | 98 | |
| Total Assets | 31 | 33 | 47 | 56 | 55 | 70 | 71 | 69 | 106 | 136 | 196 | 234 | 281 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 7 | 12 | 3 | -10 | 10 | -0 | 1 | 10 | 20 | 66 | 29 | |
| -11 | 3 | -12 | 1 | 14 | -23 | -0 | 0 | -18 | -16 | -58 | -27 | |
| -2 | -7 | -2 | -6 | -2 | 12 | -1 | -1 | 9 | -4 | -4 | -7 | |
| Net Cash Flow | -3 | 3 | -2 | -2 | 2 | -0 | -2 | 0 | 0 | -1 | 5 | -4 |
| Free Cash Flow | 6 | 8 | 1 | 1 | -11 | 1 | -2 | -3 | 7 | 9 | 60 | 27 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 123% | 119% | 95% | 55% | 305% | 295% | 13% | -30% | 45% | 67% | 107% | 80% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 9 | 9 | 21 | 29 | 59 | 31 | 91 | 42 | 72 | 67 | 43 | 72 |
| Inventory Days | 72 | 155 | 225 | 200 | 77 | 92 | 136 | 215 | 103 | 155 | 85 | 125 |
| Days Payable | 171 | 182 | 238 | 101 | 43 | 74 | 71 | 107 | 59 | 19 | 24 | 23 |
| Cash Conversion Cycle | -90 | -19 | 8 | 128 | 93 | 48 | 156 | 150 | 116 | 203 | 103 | 174 |
| Working Capital Days | -102 | -35 | 8 | 60 | 83 | 16 | 74 | 63 | 76 | 115 | 65 | 108 |
| ROCE % | 46% | 64% | 48% | 39% | 2% | 6% | 4% | -4% | 36% | 49% | 53% | 28% |
Insights
In beta| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Granted Patents (In-force) count |
|
|||||||||
| Avery Pharma FSSAI Approved Products count |
||||||||||
| Avery Pharma RX (Prescription) Approved Products count |
||||||||||
| Patent Applications in Process (Total) count |
||||||||||
| Registered Trademarks count |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Copy Of Newspaper Publication
-
Press Release On Financial Result
- Arrow Greentech reported H1 FY27 revenue of Rs. 1,733 million and PAT of Rs. 525 million.
-
Presentation On Business Performance Of The Company
- Arrow Greentech released Q2/H1 FY27 results: H1 revenue rose 68.8% to Rs. 1,733 million, PAT up 97.1%.
-
Board Meeting Outcome for Outcome Of The Board Meeting
- Board approved unaudited standalone and consolidated results for quarter/half year ended 30 September 2026.
-
Board Meeting Intimation for To Consider And Approve The Un-Audited Standalone And Consolidated Financial Results Along
With The Limited Review Report Of The Auditors Thereon, For The Quarter And Half Year Ended
September 30, 2026.
- Board meeting on 5 November 2026 to approve Q2 and H1 FY2027 results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2]
AGL is India’s largest manufacturer of
water-soluble films, specializing in the development, production, and marketing
of a diverse range of PVA /PVOH-based
films. Its portfolio includes innovative applications such as mouth-dissolving
strips for pharmaceutical and nutraceutical
use. In addition to green packaging solutions, AGL also offers advanced security products
and intellectual property services, positioning itself as a multi-vertical, technology-driven company.